2023
Mixed donor chimerism following stem cell transplantation for sickle cell disease
Shah N, Rangarajan H, Ngwube A, Shenoy S. Mixed donor chimerism following stem cell transplantation for sickle cell disease. Current Opinion In Hematology 2023, 30: 187-193. PMID: 37694765, DOI: 10.1097/moh.0000000000000786.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationDonor/recipient chimerismStem cell transplantationSickle cell diseasePost-HCTRecipient chimerismDonor chimerismCell transplantationCell diseaseDisease controlDonor-derived erythropoiesisHCT conditioning regimensMixed donor chimerismSerial chimerism analysesRecent clinical trialsDonor erythropoiesisConditioning regimensHigh morbidityCurative interventionsClinical trialsSuccessful engraftmentSCD manifestationsMyeloid cellsHb S traitChimerism analysis
2021
Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia
Gorfinkel L, Demsky C, Pashankar F, Kupfer G, Shah NC. Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia. Pediatric Transplantation 2021, 25: e14009. PMID: 33755277, DOI: 10.1111/petr.14009.Peer-Reviewed Original ResearchConceptsUnrelated donor transplantsDonor transplantsBM graftsVivo T-cell depletionReduced intensity conditioning regimenStem cell transplant programInclusion of alemtuzumabNon-TBI conditioningPost-transplant complicationsSuccess of HSCTDevelopment of GVHDT-cell depletionIntensity conditioning regimenBone marrow transplantFull immune reconstitutionChronic GVHDCyclophosphamide conditioningGVHD prophylaxisMSD transplantsImmune reconstitutionConditioning regimenLate complicationsConditioning regimensSecondary neoplasmsSecondary malignancies